Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. PREFERRED STOCK PURCHASE AGREEMENT NEURONASAL, INC.Preferred Stock Purchase Agreement • April 20th, 2021 • ATAI Life Sciences B.V. • Pharmaceutical preparations • Delaware
THIS PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 23rd day of December 2019 by and among Neuronasal, Inc., a Delaware corporation (the “Company”), and ATAI LIFE SCIENCES AG, a German stock corporation or an Affiliate thereof (“ATAI” or “Purchaser”).
Certain information in this document has been omitted from this exhibit because it is both EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 20th, 2021 • ATAI Life Sciences B.V. • Pharmaceutical preparations • New York
This Agreement is dated 6/8, 2020 (the “Effective Date”), and is between THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, a New York corporation (“Columbia”), and KURES, INC., a Delaware corporation (the “Company”). Columbia and Company agree as follows:
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. STOCK PURCHASE AGREEMENT BY AND BETWEEN ATAI US 2, INC. AND JONATHAN SPORN DATED...Stock Purchase Agreement • April 20th, 2021 • ATAI Life Sciences B.V. • Pharmaceutical preparations • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 5, 2018 by and among ATAI US 2, Inc., a Delaware corporation (the “Buyer”) and Dr. Jonathan Sporn, an individual (“Seller”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • April 20th, 2021 • ATAI Life Sciences B.V. • Pharmaceutical preparations • New York
STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of June 8, 2020, between The Trustees of Columbia University in the City of New York, a New York corporation (“Columbia”), and Kures Inc., a Delaware corporation (the “Corporation”).
AMENDED AND RESTATED LICENSE AGREEMENT between ALLERGAN SALES, LLC and FSV7, LLC Dated as of February 21, 2020License Agreement • April 20th, 2021 • ATAI Life Sciences B.V. • Pharmaceutical preparations • New York
This Amended and Restated License Agreement (this “Agreement”) is made and entered into effective as of February 21, 2020 (the “Effective Date”) by and between Allergan Sales, LLC, a Delaware limited liability company (“Allergan”) and FSV7, LLC, a Delaware limited liability company (“Licensee”). Allergan and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Certain information in this document has been omitted from this exhibit because it is both Consultancy AgreementConsultancy Agreement • April 20th, 2021 • ATAI Life Sciences B.V. • Pharmaceutical preparations
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SERIES A PREFERRED STOCK PURCHASE AGREEMENT DEMERX IB, INC.Series a Preferred Stock Purchase Agreement • April 20th, 2021 • ATAI Life Sciences B.V. • Pharmaceutical preparations • Delaware
THIS SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 27th day of December 2019 by and among DemeRx IB, Inc., a Delaware corporation (the “Company”), ATAI Life Sciences AG, a German stock corporation or an Affiliate thereof (“ATAI”) and DemeRx, Inc., a Florida corporation (“DemeRx” and together with ATAI each a “Stockholder” and together the “Stockholders”).
Certain information in this document has been omitted from this exhibit because it is both LICENSE AGREEMENTLicense Agreement • April 20th, 2021 • ATAI Life Sciences B.V. • Pharmaceutical preparations • Tokyo
This License Agreement (the “Agreement”) is entered into on the 14th of August 2017 (“Effective Date”), by and between National University Corporation Chiba University, having an address at 1-33 Yayoi-cho, Inage-ku, Chiba-shi, Chiba 263-8522 JAPAN (“Licensor”) and Perception Neurosciences, Inc. having an address at 113 University Place Suite 1019 New York, New York USA 10003 (the “Company”) (each of Licensor and the Company referred to as a “Party” and collectively as the “Parties”).
